Cerus Corp. and Grifols S.A. have agreed to commercialize Cerus' INTERCEPT Blood System in Spain and Portugal. The system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a range of pathogens, including viruses, bacteria and parasites that might be present in donated blood.

Full Story:

Related Summaries